Abridge pricing

About

Abridge is an enterprise ambient AI clinical documentation company headquartered in Pittsburgh and San Francisco. Its software listens to a patient–clinician conversation and generates a contextually aware, clinically useful, and billable note in real time, integrated directly into the EHR — with a “Linked Evidence” feature that ties each line of the draft back to what was actually said. The platform spans four surfaces: Clinician documentation, Nursing documentation, Revenue Cycle (billable/coded notes), and CDS (clinical decision support).

Abridge is one of the largest players in the ambient-scribe category. It is deployed at 150+ health systems — Mayo Clinic (2,000+ physicians), Duke Health (5,000 clinicians across 150 locations), Johns Hopkins, Kaiser Permanente, Corewell, UPMC, Emory, Memorial Sloan Kettering and dozens more — and reports deep Epic integration (Epic holds an equity stake and revenue-share relationship, reported by third parties). Sacra estimates ARR around $100M by mid-2025 (up from ~$60M at end of 2024). On funding, Abridge raised a $250M Series D in February 2025 at $2.75B, a $300M Series E in June 2025 led by a16z (with Khosla) at $5.3B, and a reported $316M Series E extension in April 2026 at the same valuation — among the fastest valuation climbs in health AI. It has been named #1 Best in KLAS for Ambient AI in Revenue Cycle two years running (most recently February 2026).

For the most current information, visit Abridge. Note: there is no public pricing page — the site routes every inquiry to Contact Us.

Pricing summary : How Abridge’s pricing model works

Abridge is fully sales-only: there is no published price list, no self-serve signup, no free tier, and no /pricing page at all — every plan, product, and CTA on the site resolves to “Contact Us.” Pricing is quoted per health-system deal. The reported structure is a per-clinician (per-seat / PEPM-style) annual license, with total contract value scaling by clinician count, encounter volume, and which modules (Clinician, Nursing, Revenue Cycle, CDS) the system attaches. Purchasing happens at the system or department level on annual enterprise commitments — an individual clinician cannot buy it directly.

Third-party trackers report an indicative per-clinician annual list figure (discussed with the specific number in Hidden costs below), positioning Abridge between lower-cost individual scribes and premium incumbents like Nuance DAX. Buyer-reported ranges run wider depending on integration depth and module mix. All such figures are third-party-reported and indicative only — Abridge does not confirm pricing publicly, and no dollar figure appears on any of its own surfaces.

What makes this different: unlike token- or request-metered AI tools elsewhere in this corpus, Abridge’s value metric is the clinician seat and the documentation it produces — a unit health systems already budget by provider headcount. Pricing is wrapped in a classic enterprise health-IT motion (EHR integration, security review, multi-year deal) rather than a published rate card, and the revenue-cycle module ties some of the value to billable, coded output, edging toward outcome-aligned value without publishing an outcome meter.

Pricing by product

Sales motions across products: sales-led only — demo → security/EHR review → custom quote → annual enterprise contract. No free tier, no monthly option, no self-serve. Third-party indicative per-clinician figures (discussed in Pricing summary) are reported, not official; treat the per-clinician number as a negotiation starting point, not a posted rate.

Hidden costs : What Abridge users actually pay

Because pricing is quoted and modular, the real cost is shaped by how many clinicians are licensed, which modules are attached, and how deep the EHR integration runs — not a published rate card. The biggest “hidden” factors health systems cite: implementation and change management (clinician training, workflow redesign, EHR build) are typically separate from the per-seat license; the revenue-cycle and nursing modules price on top of the core clinician license; and annual, multi-year commitments remove the option to pilot month-to-month at scale.

Outside the Facts table, third-party guides put list pricing around $2,500 per clinician per year (about $208/month), with wider buyer-reported ranges depending on integration depth — that puts Abridge above lightweight individual scribes (Freed is reported around $99/month) and below premium incumbents. Treat all of these as third-party-reported and indicative, not official. Other things to budget for: a multi-year commitment is common at health-system scale; total cost is opaque until you receive a quote, making apples-to-apples comparison against per-seat alternatives hard pre-sales; and value realization depends on adoption, so clinician enablement is a real (if unbilled) cost of ownership.

Want to estimate your own Abridge bill? Use the Abridge pricing calculator to model your costs based on clinician count and module mix.

Pricing evolution : Abridge pricing history and changes

Cadence

Tracked range: 2025–present. Abridge has never published a public price list, so there are no Wayback price snapshots to chart — the evolution here is funding, scale, and product modules, not posted rate cards.

Notable changes

• 2025-02 — $250M Series D at $2.75B; reports 100+ health systems and a revenue-cycle product for billable/coded notes. Pricing stays sales-only.
• 2025-06 — $300M Series E led by a16z (with Khosla) at $5.3B, nearly doubling valuation in four months; 150+ systems, ARR ~$100M.
• 2026-02 — Named #1 Best in KLAS for Ambient AI in Revenue Cycle for the second consecutive year.
• 2026-04 — Reported $316M Series E extension at $5.3B (a16z, Khosla, NVIDIA NVentures, Lightspeed, Bessemer reported); commercial model unchanged — negotiated per-clinician health-system contracts.

What’s unique : Abridge’s distinctive pricing mechanics

1. Per-clinician, not per-token. In a corpus full of token- and request-metered AI tools, Abridge prices on the clinician seat — a unit health systems already budget by provider headcount. That keeps the meter intuitive for CMIOs and CFOs but ties revenue to clinician count rather than the volume of AI work done.

2. Fully gated — no /pricing page at all. Most sales-only vendors at least keep a /pricing URL with a contact form; Abridge routes every path to “Contact Us.” Nothing is published, which maximizes negotiating leverage for an enterprise health-IT sale and keeps competitors guessing.

3. EHR integration as the moat behind the price. Pricing is wrapped in deep Epic (and multi-EHR) integration with reported equity/revenue-share ties to Epic. The switching cost isn’t the per-seat fee — it’s the embedded EHR workflow, which is what lets Abridge sell annual, multi-year, system-wide contracts rather than month-to-month seats.

Strengths & weaknesses

Billing UX : Abridge billing controls and transparency

• Billing controls — Enterprise contract-based: annual (often multi-year) commitments, no self-serve plan changes, no monthly billing. Seat counts and module changes go through the account team and contract amendments rather than an in-app toggle.
• Usage visibility — Abridge surfaces an Impact Calculator (an ROI tool) and customer-impact reporting, plus in-product documentation analytics, but there is no public cost calculator or published rate card — health systems cannot model spend without a sales conversation.
• Payment options — Invoiced annual enterprise contracts via direct sales, scoped to the system’s clinician count, modules, and EHR integration. Implementation and enablement services are typically separate line items.

Strategic wins : Why Abridge’s pricing decisions worked

1. Pricing on a metric health systems already trust

Anchoring on the clinician seat lets Abridge sell into provider budgets organized by headcount, sidestepping the “what’s a token?” education problem that pure-usage AI tools face. See how AI companies structure pricing.

2. Modular packaging to expand accounts

Selling Clinician, Nursing, Revenue Cycle, and CDS as separate modules creates a natural land-and-expand path — start with physician documentation, add nursing and revenue cycle later — growing contract value without renegotiating the core seat license. Related: outcome-based pricing trends.

3. EHR integration as the durable lock-in

By embedding deep into Epic and other EHRs (with reported equity/revenue-share ties to Epic), Abridge turns the documentation workflow into the switching cost — letting it command annual, system-wide contracts at premium per-clinician rates. See choosing the right usage metric.

Areas to improve : Gaps in Abridge’s pricing approach

1. Zero pricing transparency

No /pricing page and no published rate card force every buyer into a sales motion just to learn rough cost. Even a posted “starting at” or a public methodology would reduce friction for the many health systems now comparing ambient scribes head-to-head. See bill shock and cost unpredictability.

2. Seat metric vs. automation thesis

As AI documentation does more of the work, a per-clinician seat fee can feel disconnected from the actual volume of notes, encounters, and coded output produced. An outcome- or encounter-aligned meter (notes generated, billable codes captured) would keep price and value aligned as the product scales.

3. High floor blocks smaller buyers

The enterprise-only motion (annual, multi-year, system-wide) shuts out small practices and individual clinicians, who are served instead by self-serve scribes like Freed. A lighter, published SKU for small groups would widen the funnel without undermining the health-system motion.

Key takeaways

1. Abridge publishes nothing — pricing is fully sales-only. There is no /pricing page at all; expect a negotiated per-clinician (per-seat / PEPM-style) annual contract scaled by clinician count and modules.
2. The value metric is the clinician seat. Third parties report roughly $2,500 per clinician per year (~$208/month), but that is third-party-reported and indicative only — Abridge confirms no figures.
3. Annual, enterprise-only, no free tier. Purchasing happens at the health-system level on multi-year commitments — there is no self-serve or individual-clinician path.
4. Modules drive expansion. Clinician, Nursing, Revenue Cycle, and CDS price separately, so identical clinician counts can cost very differently depending on what’s attached.
5. EHR integration is the moat. Deep Epic integration (with reported equity/revenue-share ties) is what lets Abridge hold premium, sticky, system-wide contracts.

UBP implications

1. Seat-based is durable where buyers budget by headcount, but it ages awkwardly when the product’s job is to automate the documentation work — every ambient-scribe vendor will eventually face pressure toward encounter- or outcome-aligned meters. See usage-based pricing strategy.
2. Full opacity is a deliberate enterprise choice, trading shorter sales cycles for negotiating leverage; it works at high ACV with deep EHR integration but blocks the bottom-up adoption that powers self-serve competitors.
3. The revenue-cycle module hints at outcome alignment — billing on billable/coded output is closer to value than a flat per-seat fee, and is the most likely path by which ambient-scribe pricing evolves from seats toward outcomes.

Sources

• Abridge official website (live capture, accessed 2026-06-10)
• Abridge — Clinicians platform (live capture, accessed 2026-06-10)
• Abridge — Customers / press (live capture, accessed 2026-06-10)
• Abridge — Contact (no /pricing page; routes to Contact Us) (live capture, accessed 2026-06-10)
• Sacra — Abridge revenue, valuation & funding (~$2,500/clinician/year, ARR ~$100M) (third-party, accessed 2026-06-10)
• FierceHealthcare — Abridge scores $300M Series E at $5.3B (accessed 2026-06-10)
• TechCrunch — Abridge doubles valuation to $5.3B in four months (accessed 2026-06-10)
• Abridge — Series E announcement (accessed 2026-06-10)
• FierceHealthcare — Abridge $250M Series D, 100+ health systems (accessed 2026-06-10)

Bottom line

Abridge is an a16z-backed (~$5.3B valuation) enterprise ambient-AI clinical documentation company — real-time, EHR-integrated notes for clinicians, nursing, and revenue cycle, deployed at 150+ health systems including Mayo, Duke, and Johns Hopkins. Its pricing is fully sales-only with no public list and no /pricing page (the site routes everything to Contact Us): a negotiated per-clinician (per-seat / PEPM-style) annual contract, scaled by clinician count, encounter volume, and modules, on annual enterprise commitments. Third parties cite roughly $2,500 per clinician per year — indicative only, never confirmed by Abridge. The open question is whether a per-clinician seat model survives as ambient AI does ever more of the documentation work, with the revenue-cycle module pointing toward outcome-aligned pricing. Browse the pricing blueprint for more fully-researched company profiles.

Want to compare Abridge against other healthcare and AI-documentation companies? Browse the pricing blueprint.